What does Omnicell do and what are its main business segments?

What were the key takeaways from Omnicell’s earnings call?

What is Omnicell's gross profit margin?

What were the key takeaways from Omnicell's earnings call?

What factors drove the changes in Omnicell's revenue and profit?

What is Omnicell's latest dividend and current dividend yield?

What is the market's earnings forecast for Omnicell next quarter?

What guidance did Omnicell's management provide for the next earnings period?

- **Revenue Beat**: Q3 revenue $311M (+10% YoY), Non-GAAP EPS $0.51 vs. $0.56 prior year. Full-year guidance raised to $1.177B-$1.187B.
- **OmniSphere Expansion**: 60+ customers migrating to cloud platform; early adopters report efficiency gains. HITRUST-certified security.
- **Tariff Mitigation**: $6M Q3 impact, 2025 total $15M. 2026 actions to reduce impact below Q4 2025 run rate.
- **Innovation Push**: Modular robots, AI-driven pharmacy solutions, and ASHP 2025 product showcase.
- **340B Growth**: Over 50% new contracts from existing customers, ARR $610M-$630M.

**【CEO Summary Section】**
- **Revenue Growth**: Total revenue of $311 million, up 10% YoY, driven by point-of-care solutions like XTExtend. Non-GAAP EPS was $0.51, exceeding expectations.
- **OmniSphere Momentum**: Cloud-based platform achieved HITRUST certification, with early adopters and plans for full customer migration. Expansion into outpatient settings and government facilities.
- **Strategic Pillars**: Market expansion (nursing units, ORs), service contracts (subscriptions, software), and technology acceleration (AI, robotics). Completed $75M stock buyback, reducing shares by 5%.
- **Innovation Focus**: Autonomous pharmacy vision with AI and robotics; new compounding robot in limited release. ASHP 2025 showcase for new innovations.

**【CFO Financial Commentary】**
- **Financial Highlights**: Q3 GAAP EPS $0.12, Non-GAAP EPS $0.51. Gross margin 44.2%. Free cash flow $14M, down from $27M prior quarter. Tariffs impacted Q3 profitability by $6M, expected to continue in Q4.
- **Guidance Update**: Full-year revenue raised to $1.177B-$1.187B, up from $1.13B-$1.16B. Non-GAAP EBITDA $140M-$146M, up from $130M-$145M. ARR $610M-$630M.
- **Tariff Mitigation**: Supply chain diversification to reduce 2026 impact. Q4 revenue $306M-$316M, EBITDA $37M-$43M.

**【Q&A Highlights】**
- **Robotics & Hardware**: Exploring humanoid robots for pharmacy; smaller, modular dispensing robots in development. Robotics integration into current products for efficiency.
- **OmniSphere Adoption**: 60+ customers on OmniCenter migrating to OmniSphere. Early adopters report improved visibility and efficiency.
- **IV Opportunity**: Ballad Health win for IV workflow solutions. Hub-and-spoke model based on health system size and throughput needs.
- **340B Growth**: Over half of new 340B contracts from existing customers. Regulatory headwinds offset by hospital focus on ROI, ARR growth expected.
- **Sales Cycle**: Consistent pipeline momentum, no significant cycle changes. Focus on point-of-care products with limited release compounding robot.
- **Tariff Impact**: Q3/Q4 $6M net impact, 2025 total $15M. 2026 mitigation efforts to reduce impact below Q4 2025 run rate.

Omnicell, Inc. (OMCL) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

OMCL

OMCL fundamentals

You can ask Aime